Cited by 197Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsGenetic Associations and Epidemiology

Genome-wide association study of the rate of cognitive decline in Alzheimer’s disease

Open access
Sherva, Richard, Tripodis, Yorghos, Bennett, David A., Chibnik, Lori B., Crane, Paul K., de Jager, Philip L., Farrer, Lindsay A., Saykin, Andrew J. +4 more·2014·Alzheimer's & Dementia

Abstract

Background: Substantial interindividual variability exists in the disease trajectories of Alzheimer's disease (AD) patients. Some decline rapidly whereas others decline slowly, and there are no known explanations for this variability. We describe the first genome‐wide association study to examine rate of cognitive decline in a sample of AD patients with longitudinal measures of cognition. Methods: The discovery sample was 303 AD cases recruited in the Alzheimer's Disease Neuroimaging Initiative and the replication sample was 323 AD cases from the Religious Orders Study and Rush Memory and Aging Project. In the discovery sample, Alzheimer's Disease Assessment Scale–cognitive subscale responses were tested for association with genome‐wide single‐nucleotide polymorphism (SNP) data using linear regression. We tested the 65 most significant SNPs from the discovery sample for association in the replication sample. Results: We identified SNPs in the spondin 1 gene ( SPON1 ), the minor alleles of which were significantly associated with a slower rate of decline (rs11023139, P = 7.0 × 10 −11 ) in the discovery sample. A SPON1 SNP 5.5 kb upstream was associated with decline in the replication sample (rs11606345, P = .002). Conclusion: SPON1 has not been previously associated with AD risk, but is plausibly related because the gene product binds to the amyloid precursor protein and inhibits its cleavage by β‐secretase. These data suggest that SPON1 may be associated with the differential rate of cognitive decline in AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2013.01.008

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Loci reaching GWAS and nominal significance and SNPs in LD with them at D' ≥ 0.8 show predominant associations with traits such as cognitive decline, educational attainment, mean bone density, intelligence and performance intelligence quotient, and soluble TREM-2 levels.

    “Analysis of loci that reach GWAS and nominal significance and SNPs in LD with them at D’ ≥ 0.8 reveals predominant associations with traits such as cognitive decline [12, 68, 69], educational attainment [70–73], mean bone density [57, 74], intelligence and performance intelligence quotient [75, 76] and soluble TREM-2 levels [77].”
  • Genome-wide analyses have often been confounded by the absence of disease confirmatory biomarkers such as amyloid, which is critical given the high rate of clinical misdiagnosis.

    “Lastly, genome wide analyses have often been confounded by the absence of disease confirmatory biomarkers such as amyloid, which is critical given the high rate of clinical misdiagnosis[12–14].”

    From Genetic drivers of progression in Alzheimer’s disease are distinct from disease risk (2026) · cites this paper as [12]

    The Methods (Discovery Sample; page unavailable) describe biomarker collection in ADNI and define baseline by clinical AD diagnosis. The Discussion (page unavailable) identifies other study limitations, but neither passage says that missing confirmatory biomarkers often confound genome-wide analyses or that clinical misdiagnosis is common. Searches for those points found no supporting passage in our copy. (LLM, conf=0.72)

    Experimental — accuracy not yet measured
  • APOE and APP are among the most significant genetic risk factors for AD.

    “In addition, we found the APOE and APP subnetwork within the vesicle mediated transport pathway which are among the most significant genetic risk factors for AD (Figure 5F).46,47,48”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 34 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Sherva, R., Tripodis, Y., Bennett, D. A., Chibnik, L. B., Crane, P. K., de Jager, P. L., Farrer, L. A., Saykin, A. J., Shulman, J. M., Naj, A., Green, R. C., & The GENAROAD Consortium, T. A. D. N. I.
Affiliations
  • Boston University (US)
  • Department of Medicine (Biomedical Genetics) Boston University School of Medicine Boston MA USA
Corresponding author
Sherva, Richard
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2013-03-26
Volume
10
Issue
1
Pages
45-52
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2034937783
Cited by
180
References
34
Citations by year
2026: 4 · 2025: 6 · 2024: 23 · 2023: 18 · 2022: 15 · 2021: 15 · 2020: 18 · 2019: 12 · 2018: 14 · 2017: 15 · 2016: 11 · 2015: 11 · 2014: 14 · 2013: 3 · 2012: 1
FWCI
9.21
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (U01 AG024904)
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
  • Dana Foundation (HG02213, AG027841)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
Alzheimer's disease
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Cognition Disorders, Female, Follow-Up Studies, Genotype, Humans, Male, Neuropsychological Tests, Phenotype, Extracellular Matrix Proteins, Polymorphism, Single Nucleotide, Apolipoprotein E4, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review